ArticleResearch square2026

A Phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB).

John-Paul Taylor et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.